ENNO-002

ENNO-002 is a preclinical-stage biologic candidate being developed by Ennovate Pharma for the treatment of autoimmune and inflammatory diseases. The program focuses on the development of monovalent and bifunctional or bispecific biologics designed to modulate the activity of mast cells and eosinophils, which are key drivers of allergic and inflammatory responses. By targeting these specific immune cell populations, ENNO-002 aims to provide a targeted therapeutic approach for conditions characterized by immune dysregulation. As of early 2024, the program is in the hit identification phase of preclinical development.